Table 1.
Longitudinal Changes in Serum Albumin Concentrations in Studies of Protein-Leaking Dialyzers
| Study Author (Yr/Country) | Patients (N) Study Duration | Protein-Leaking Dialyzer | High Flux Dialyzer | ||
|---|---|---|---|---|---|
| Baseline Serum Albumin, g/dl (Dialyzer Studied) | Change in Serum Albumin, g/dl | Baseline Serum Albumin, g/dl (Dialyzer Studied) | Change in Serum Albumin, g/dl | ||
| Zickler et al64 (2017/Germany) |
48 4 + 8 wk (extension) |
3.70 (0.36) (MCO-Ci 400) |
▼ 0.17 (4 wk) ▼ 0.06 (12 wk) |
3.66 (0.32) (Revaclear 400 dialyzer) |
▲ 0.09 (4 wk) ▲ 0.12 (12 wk) |
| Cozzolino et al65 (2019/Italy) |
20 3 mo |
Group A 3.75 (3.10 to 3.80) Group B 3.80 (3.30 to 4.20) (Theranova 400) |
Group A ▲ 0.04 (0.175 to 0.375) Group B ▼ 0.45 (–0.575 to –0.05) |
Group A 3.6 (3.35 to 3.80) Group B 3.47 (3.05 to 3.80) (FX8, FX10, FX80, FX 100, BK1.6, BG2.1) |
Group A ▲ 0.1 (–0.525 to 0.175) Group B ▲ 0.34 (0.125 to 0.40) |
| Belmouaz et al66 (2020/France) |
40 6 mo |
3.73 (0.31) (Theranova 500) |
▼ 0.04 | 3.73 (0.31) (Elisio™-21H) |
▲ 0.09 |
| Krishnasamy et al71 (2020/Australia) |
89 24 wk |
3.58 (0.39) (Theranova 400) |
▼ 0.07 (–1.5 to 0.1)* | No control group | No control group |
| Lim et al69 (2020/South Korea) |
49 12 wk |
4.11 (0.38) (Theranova 400) |
▼ 0.13 | 4.06 (0.27) (FX CorDiax 60 or 80) |
▼ 0.02 |
| Sevinc et al70 (2020/Turkey) |
52 3 mo |
3.88 (3.71 to 4.04) (Theranova 500) |
▼ 0.26 | 3.75 (3.59 to 3.95) (FX CorDiax 80) |
▲ 0.03 |
| Bunch et al67 (2020/Colombia) |
992 12 mo |
4.05 (4.04 to 4.07) (Theranova MCO dialyzer) |
▼ 0.14 (3 mo) ▼ 0.07 (12 mo) |
No control group | No control group |
| Yeter et al68 (2020/Turkey) |
42 6 mo |
4.0 (0.25) (Theranova 400) |
▼ 0.16 | 3.96 (0.23) (Fresenius CorDiax 800 HDF) |
▼ 0.07 |
Notes: Data listed as mean, mean (SD), or median (interquartile range) unless otherwise noted. *Data listed as mean (95% CI). ▼=reduction from baseline; ▲=increase from baseline.